{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000079","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.268439+00:00","generated_at":"2026-06-05T12:17:16.374256+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zentalis reports FY2023 cash $483M, azenosertib ORR 37%, appoints CMO/CBO","bullets":["Cash, equivalents and securities $482.9M at Dec 31, 2023; runway into 2026; plus $35M upfront from Immunome in Jan 2024.","R&D expenses $189.6M (up 9.8%), G&A $64.4M (up 18%) versus FY2022.","Azenosertib Phase 1 monotherapy showed 37% ORR and 6.5-month mPFS in platinum-resistant ovarian/USC cancer patients.","Appointed Diana Hausman, M.D., as CMO and Kyle Rasbach, Ph.D., Pharm.D., as CBO.","NDA submission for azenosertib in gynecologic malignancy targeted for 2026; multiple data readouts in 2024-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000079","json":"https://secwatch.observer/filing/0001725160-24-000079.json","markdown":"https://secwatch.observer/filing/0001725160-24-000079.md","text":"https://secwatch.observer/filing/0001725160-24-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/0001725160-24-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/zntl-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:17:16.374256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f60d164333494ebea15342304d18d969a290b2e","claim":"Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/0001725160-24-000079-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}